Education
About Us
Working with TipRanks
Follow Us
Lipigon Pharmaceuticals AB (DE:9RP)
:9RP
9RP Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.00 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)4.83K
Market Cap
€5.42M
Enterprise Value€124.97M
Total Cash (Recent Filing)€10.74M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta68.25
Next Earnings
May 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding563,655,940
10 Day Avg. Volume0
30 Day Avg. Volume4,825
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
9RP FAQ
What was Lipigon Pharmaceuticals AB’s price range in the past 12 months?
Lipigon Pharmaceuticals AB lowest stock price was €0.00 and its highest was €0.02 in the past 12 months.
What is Lipigon Pharmaceuticals AB’s market cap?
Lipigon Pharmaceuticals AB’s market cap is €5.42M.
When is Lipigon Pharmaceuticals AB’s upcoming earnings report date?
Lipigon Pharmaceuticals AB’s upcoming earnings report date is May 27, 2025 which is 33 days ago.
How were Lipigon Pharmaceuticals AB’s earnings last quarter?
Lipigon Pharmaceuticals AB released its earnings results on Feb 19, 2025. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.005.
Is Lipigon Pharmaceuticals AB overvalued?
According to Wall Street analysts Lipigon Pharmaceuticals AB’s price is currently Overvalued.
Does Lipigon Pharmaceuticals AB pay dividends?
Lipigon Pharmaceuticals AB does not currently pay dividends.
What is Lipigon Pharmaceuticals AB’s EPS estimate?
Lipigon Pharmaceuticals AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipigon Pharmaceuticals AB have?
Lipigon Pharmaceuticals AB has 563,655,940 shares outstanding.
What happened to Lipigon Pharmaceuticals AB’s price movement after its last earnings report?
Lipigon Pharmaceuticals AB reported an EPS of -€0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lipigon Pharmaceuticals AB?
Currently, no hedge funds are holding shares in DE:9RP
Company Description
Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.
Technical Analysis
LIDDS AB
―
Scandion Oncology A/S
―
Spago Nanomedical AB
―
CombiGene AB
―
QuiaPEG Pharmaceuticals Holding AB
―